Agendia announced that the FDA cleared its MammaPrint® breast cancer recurrence test for all ages.
MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians. Over the past three years, the FDA has issued four clearances for MammaPrint, covering all aspects of this important service.
"This FDA clearance, along with our recently obtained CMS coverage for all stage I and II breast cancer patients, including patients with up to three positive lymph nodes, will facilitate our discussions with healthcare providers about patients’ eligibility criteria for MammaPrint," said Dr. Bernhard Sixt, Agendia’s Chief Executive Officer.
"This new clearance confirms the opinion of the international medical community that MammaPrint carries clinical utility and is safe and effective in breast cancer patients of all ages," said Dr. Richard Bender, Chief Medical Officer of Agendia. "Seeking clearance for all ages further demonstrates Agendia’s commitment to provide patients and physicians with high quality FDA-cleared tests to help guide vital treatment decisions." In Europe, MammaPrint has been approved for all ages since 2004.
Source: Agendia BV
